Detail akcie Vetoquinol online

Business Summary: Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Vetoquinol SA revenues decreased 3% to EUR257.6M. Net income increased 5% to EUR25.1M. Revenues reflect Americas segment decrease of 12% to EUR34.4M, Europe segment decrease of 2% to EUR139.6M, USA segment decrease of 2% to EUR53.8M. Net income reflects USA segment income increase from EUR2M to EUR5M, Asia Pacific (rest of world) segment income increase of 8% to EUR3.7M.